Online citations, reference lists, and bibliographies.
← Back to Search

Biomechanical Effects Of Teriparatide In Women With Osteoporosis Treated Previously With Alendronate And Risedronate: Results From Quantitative Computed Tomography-based Finite Element Analysis Of The Vertebral Body.

Y. Chevalier, Evelyn Quek, B. Borah, G. Gross, J. Stewart, T. Lang, P. Zysset
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Previous antiresorptive treatment may influence the anabolic response to teriparatide. The OPTAMISE (Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide) study reported greater increases in biochemical markers of bone turnover and volumetric bone mineral density (BMD) when 12 months of teriparatide treatment was preceded by 2 years or more of risedronate versus alendronate treatment. The objective of this study was to use quantitative computed tomography (CT)-based nonlinear finite element modeling to evaluate how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the biomechanical effectiveness of teriparatide. Finite element models of the L1 vertebra were created from quantitative CT scans, acquired before and after 12 months of therapy with teriparatide, from 171 patients from the OPTAMISE study. These models were subjected to uniaxial compression. Total BMD-derived bone volume fraction (BV/TV(d), i.e., bone volume [BV]/total volume [TV]), estimated from quantitative CT-based volumetric BMD, vertebral stiffness, and failure load (strength) were calculated for each time measurement point. The results of this study demonstrated that 12 months of treatment with teriparatide following prior treatment with either risedronate or alendronate increased BMD-derived BV/TV(d), the predicted vertebral stiffness, and failure load. However, the effects of teriparatide were more pronounced in patients treated previously with risedronate, which is consistent with the findings of the OPTAMISE study. The mean (+/-standard error) increase in stiffness was greater in the prior risedronate group than the prior alendronate group (24.6+/-3.2% versus 14.4+/-2.8%, respectively; p=0.0073). Similarly, vertebral failure load increased by 27.2+/-3.5% in the prior risedronate group versus 15.3+/-3.1% in the prior alendronate group (p=0.0042). The mechanical variables increased in greater proportion than BV/TV(d), which increased by 6.9+/-0.9% versus 4.6+/-0.8% in the prior-risedronate and prior-alendronate groups, respectively (p=0.0290). Our finding indicated that while teriparatide can be used with success on patients who have previously undergone treatment with risedronate and alendronate, it demonstrated greater anabolic effect on biomechanical properties in prior-risedronate patients in the first year of teriparatide treatment.
This paper references
10.1007/s00198-008-0750-8
Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method
K. Imai (2008)
10.1016/J.BONE.2005.05.003
Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
G. H. Nancollas (2006)
10.1097/00004728-199901000-00027
Assessment of vertebral bone mineral density using volumetric quantitative CT.
T. Lang (1999)
Erratum: 1991 Classification of vertebral fractures (J Bone Miner Res 6:207-215)
R. Eastell (1991)
10.1016/S8756-3282(97)00072-0
Volumetric quantitative computed tomography of the proximal femur: precision and relation to bone strength.
T. Lang (1997)
10.1016/J.BONE.2007.10.021
Bone mineralization density distribution in health and disease.
P. Roschger (2008)
10.1210/JC.2003-1703
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.
H. Dobnig (2005)
10.1359/JBMR.050105
Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis
P. Chen (2005)
10.1172/JCI116872
The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.
R. Balena (1993)
10.1359/jbmr.2002.17.1.11
Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density
B. Riggs (2002)
10.1359/jbmr.061011
Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis
T. M. Keaveny (2007)
10.1080/10255840802078022
A patient-specific finite element methodology to predict damage accumulation in vertebral bodies under axial compression, sagittal flexion and combined loads
Y. Chevalier (2008)
10.1359/jbmr.040117
Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate
B. Ettinger (2004)
10.1007/s10237-008-0125-2
A three-dimensional elastic plastic damage constitutive law for bone tissue
D. García (2009)
10.1359/jbmr.2001.16.1.157
Intermittently Administered Human Parathyroid Hormone(1–34) Treatment Increases Intracortical Bone Turnover and Porosity Without Reducing Bone Strength in the Humerus of Ovariectomized Cynomolgus Monkeys
D. Burr (2001)
10.1016/j.bone.2008.05.023
Identification of material parameters based on Mohr-Coulomb failure criterion for bisphosphonate treated canine vertebral cancellous bone.
X. Wang (2008)
10.1016/8756-3282(92)90196-4
Implications of architecture for the pathogenesis and prevention of vertebral fracture.
A. Parfitt (1992)
10.1056/NEJMRA053077
Bone quality--the material and structural basis of bone strength and fragility.
E. Seeman (2006)
10.1007/s00198-007-0460-7
Fracture risk remains reduced one year after discontinuation of risedronate
N. Watts (2007)
10.1210/JC.2006-1404
Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials.
S. Boonen (2007)
10.1056/NEJMOA031975
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
D. Black (2003)
10.1016/S8756-3282(01)00467-7
The influence of bone volume fraction and ash fraction on bone strength and modulus.
C. Hernandez (2001)
10.1002/JBMR.5650060302
Classification of vertebral fractures
R. Eastell (1991)
10.1007/s00198-007-0540-8
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. Russell (2007)
10.1359/jbmr.090416
Improvements in Vertebral Body Strength Under Teriparatide Treatment Assessed In Vivo by Finite Element Analysis: Results From the EUROFORS Study
C. Graeff (2009)
10.1097/BRS.0b013e31815e3993
In Vivo Assessment of Lumbar Vertebral Strength in Elderly Women Using Computed Tomography-Based Nonlinear Finite Element Model
K. Imai (2008)
10.1115/1.3212097
The role of cortical shell and trabecular fabric in finite element analysis of the human vertebral body.
Y. Chevalier (2009)
10.1097/01.brs.0000142435.90314.3b
Relationship Between Axial and Bending Behaviors of the Human Thoracolumbar Vertebra
R. Crawford (2004)
10.1210/jc.2008-0353
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
P. Miller (2008)
10.1001/JAMA.296.24.2927
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
D. Black (2006)
10.1210/JC.2007-0711
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
S. Boonen (2008)



This paper is referenced by
10.1016/j.medengphy.2019.05.007
Evaluation of the capability of the simulated dual energy X-ray absorptiometry-based two-dimensional finite element models for predicting vertebral failure loads.
Yongtao Lu (2019)
10.1016/j.bone.2015.06.025
Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology.
P. Zysset (2015)
10.1016/B978-0-12-803581-8.09798-8
3.10 Finite Element Analysis in Bone Research: A Computational Method Relating Structure to Mechanical Function☆
D. Ruffoni (2017)
10.1007/s00198-013-2379-5
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis
P. Farahmand (2013)
10.1007/s11914-010-0031-2
Biomechanics of Vertebral Fractures and the Vertebral Fracture Cascade
B. Christiansen (2010)
10.1185/03007995.2011.573545
Sequential therapy in the treatment of osteoporosis
S. Boonen (2011)
10.1002/jbmr.1870
Comparative Effects of Teriparatide and Risedronate in Glucocorticoid-Induced Osteoporosis in Men: 18-Month Results of the EuroGIOPs Trial
C. Glueer (2013)
10.1016/J.YEND.2011.04.028
Association of Hip Strength Estimates by Finite Element Analysis with Fractures in Women and Men
B. Clarke (2011)
10.1097/BOR.0000000000000405
Skeletal assessment with finite element analysis: relevance, pitfalls and interpretation
Graeme M Campbell (2017)
10.1017/S2040174412000116
Isoflavone exposure throughout suckling results in improved adult bone health in mice.
Elsa C. Dinsdale (2012)
10.1016/j.medengphy.2016.06.011
Quantifying trabecular bone material anisotropy and orientation using low resolution clinical CT images: A feasibility study.
S. Nazemi (2016)
10.1185/03007995.2013.809335
Changing trends in osteoporosis care from specialty to primary care physicians
Nahid J Rianon (2013)
10.1016/j.jbspin.2011.09.014
Sequential osteoporosis treatments.
Karine Briot (2011)
10.1530/EJE-11-0740
Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
F. Jakob (2012)
10.1007/8415_2011_81
Bisphosphonates and PTH for Preventing Fractures
David B. Burr (2012)
10.1115/1.4006688
A patient-specific computer tomography-based finite element methodology to calculate the six dimensional stiffness matrix of human vertebral bodies.
Yan Chevalier (2012)
10.1002/jbmr.2024
Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
T. M. Keaveny (2014)
10.1016/j.bone.2011.10.002
Femoral strength in osteoporotic women treated with teriparatide or alendronate.
T. M. Keaveny (2012)
10.1080/10255842.2011.636741
Simulation of the behaviour of the L1 vertebra for different material properties and loading conditions
Ibrahim Erdem (2013)
10.1016/j.jbiomech.2014.04.015
Finite element analyses of human vertebral bodies embedded in polymethylmethalcrylate or loaded via the hyperelastic intervertebral disc models provide equivalent predictions of experimental strength.
Yongtao Lu (2014)
Award Number: W81XWH-13-1-0129 TITLE: MAXIMIZING PTH ANABOLIC OSTEOPOROSIS THERAPY PRINCIPAL INVESTIGATOR: JOSEPH BIDWELL CONTRACTING ORGANIZATION: TRUSTEES OF INDIANA
B. Diamond (2018)
10.1177/0954411914558654
The effect of in situ/in vitro three-dimensional quantitative computed tomography image voxel size on the finite element model of human vertebral cancellous bone
Yongtao Lu (2014)
10.1002/jbmr.347
Association of hip strength estimates by finite‐element analysis with fractures in women and men
S. Amin (2011)
10.1016/j.medengphy.2015.03.007
Finite element analysis predicts experimental failure patterns in vertebral bodies loaded via intervertebral discs up to large deformation.
Allison L. Clouthier (2015)
10.1016/S1169-8330(11)70041-2
Rotation des traitements anti-ostéoporotiques
Karine Briot (2011)
10.4414/smw.2014.13952
The role of teriparatide in sequential and combination therapy of osteoporosis.
C. Meier (2014)
10.11138/ccmbm/2016.13.1.029
Use of MR-based trabecular bone microstructure analysis at the distal radius for osteoporosis diagnostics: a study in post-menopausal women with breast cancer and treated with aromatase inhibitor.
T. Baum (2016)
Effects of teriparatide co mpared with risedronate in the treatment of osteoporosis A meta-analysis of randomized controlled trials
Chengzhi Yang (2020)
10.1007/s00223-011-9500-6
Teriparatide in Bisphosphonate-Resistant Osteoporosis: Microarchitectural Changes and Clinical Results After 6 and 18 months
B. Jobke (2011)
10.1016/j.jmbbm.2014.10.016
Compressive strength of elderly vertebrae is reduced by disc degeneration and additional flexion.
Ghislain Maquer (2015)
10.1016/j.bone.2012.09.006
A nonlinear QCT-based finite element model validation study for the human femur tested in two configurations in vitro.
E. Dallara (2013)
Development, validation and clinical evaluation of a subject-specific finite element model of the vertebra with adjacent intervertebral disc to estimate vertebral strength
Chuhee Lee (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar